Methylmalonic acidemia, cobalamin disorders

The cobalamin disorders that cause methylmalonic acidemia are a separate clinical and biochemical category from mutase-deficiency MMA. The biochemistry overlaps because both groups produce elevated methylmalonic acid in blood and urine. The treatment, the natural history, and the prognosis are different. Some cobalamin disorders respond completely to high-dose vitamin B12 and produce a benign clinical course. Others, particularly cblC, have severe multisystem disease that B12 only partially controls.

The clinical question at diagnosis is which cobalamin pathway gene is involved, because the answer determines whether the child has a vitamin-responsive disease or a complex multisystem disorder where B12 is part of the management but not the central treatment.

What the cobalamin disorders are

Vitamin B12 (cobalamin) is converted inside cells to two active cofactors: methylcobalamin, which methionine synthase requires for the remethylation of homocysteine to methionine, and adenosylcobalamin, which methylmalonyl-CoA mutase requires for the conversion of methylmalonyl-CoA to succinyl-CoA. The enzymes that import, transport, and modify cobalamin to produce both active forms are encoded by a series of genes labeled by their complementation groups: cblA, cblB, cblC, cblD, cblE, cblF, cblG, cblJ, and others.

Defects in cblA (MMAA) and cblB (MMAB) impair adenosylcobalamin synthesis specifically and produce isolated methylmalonic acidemia, with elevated methylmalonic acid in blood and urine and normal homocysteine. Both forms are typically responsive to high-dose hydroxocobalamin or cyanocobalamin given parenterally.

Defects in cblC (MMACHC) impair the conversion of cobalamin to both methylcobalamin and adenosylcobalamin and therefore produce combined methylmalonic acidemia and homocystinuria. cblC is the most common cobalamin disorder and the most clinically severe of the group, with multisystem disease that includes feeding difficulties, failure to thrive, hypotonia, neurological abnormalities, retinopathy, and hemolytic uremic syndrome in some cases. The clinical course of cblC is partially controlled by high-dose hydroxocobalamin plus betaine, folinic acid, and a methionine-sufficient diet, but residual disease burden in cblC is substantial in many cases.

Defects in cblD, cblF, cblJ, and other transport-related genes produce variable combinations of methylmalonic acidemia and homocystinuria with phenotypes that depend on the specific gene and variant. cblE and cblG produce isolated homocystinuria without methylmalonic acidemia and are covered with the homocystinuria conditions.

Reported incidence for the combined cobalamin disorders runs roughly 1 in 50,000 to 1 in 100,000 in unselected populations, with cblC accounting for the majority.

Detection

Newborn screening flags elevated propionylcarnitine, C3, and an elevated C3 to acetylcarnitine ratio, the same screening signal that identifies propionic acidemia and mutase-deficiency MMA. The cobalamin disorders are distinguished from those conditions by the second-tier testing pattern: elevated methylmalonic acid (excluding propionic acidemia), elevated total plasma homocysteine when combined methylmalonic acidemia and homocystinuria is present (cblC, cblD-MMA-HC, cblF, cblJ), and the cobalamin response on biochemical follow-up.

Confirmation requires complementation analysis on cultured fibroblasts, which establishes the specific cblA through cblJ classification, plus targeted sequencing of the relevant cobalamin pathway gene. Newborn screening for cblC specifically can produce false-negative results in some affected infants because methylmalonic acid elevation in cblC is variable and can be subtle in the first days of life; some programs have moved toward total homocysteine as a second-tier marker to improve sensitivity.

What management looks like

For cblA and cblB, standard of care is high-dose intramuscular or subcutaneous hydroxocobalamin or cyanocobalamin. Many cases respond completely or near-completely with normalization of methylmalonic acid excretion and prevention of metabolic decompensations. Mild dietary modifications and L-carnitine supplementation are used as adjuncts. The overall course in B12-responsive cblA and cblB is much milder than in mutase-deficiency MMA.

For cblC, standard of care is high-dose intramuscular or subcutaneous hydroxocobalamin (typical dose 1 mg daily, sometimes more), oral betaine to lower homocysteine through alternative remethylation, oral folinic acid, and a methionine-sufficient diet (to support remethylation). Despite optimal treatment, residual disease burden is substantial in many cases of early-onset cblC. Retinopathy, intellectual disability, and seizures can develop or progress. Late-onset cblC, presenting in older children or adults, has a milder course.

For the rare cobalamin transport defects (cblF, cblJ, transcobalamin deficiency), management is high-dose parenteral cobalamin plus condition-specific adjuncts. Phenotypes vary widely.

Hemolytic uremic syndrome can complicate cblC and cblD, sometimes as the presenting manifestation in older children. Recognition of this association has expanded testing for cobalamin disorders in atypical hemolytic uremic syndrome cases.

What this looks like for a family

A baby is born and the heel-prick is sent. On day 4, the state lab reports an elevated C3. On day 5, urine organic acids show methylmalonic acid and plasma total homocysteine is elevated, distinguishing cblC from mutase-deficiency MMA and from B12-responsive isolated MMA. Hydroxocobalamin is started by injection. Betaine and folinic acid begin orally. Methionine intake is monitored.

Over the next year, methylmalonic acid and homocysteine come down on therapy but do not normalize completely. Developmental surveillance shows mild delays. Ophthalmology surveillance for retinopathy begins. The metabolic team manages the medication routine. The family lives within an integrated care plan that combines a metabolic clinic, a developmental pediatrician, and an ophthalmologist who has seen cblC before.

That is what cobalamin-disorder MMA care looks like in practice. The diagnosis at birth shifts the trajectory away from the catastrophic infant decompensations the unscreened cohorts experienced. The residual clinical course in cblC is a multisystem disorder that vitamin therapy improves but does not resolve.